


**Imexhs Limited – (Asx: Ime)** Corporate presentation

Leading Medical Imaging Solutions Company Currently Operating in 11 Countries in LatAm.

5 March 2019



# Company Highlights

- Established next generation Radiology and Imaging Software platform
- IME founded in 2012
- Current operations in Colombia, Peru, Mexico, Ecuador and Costa Rica.
- 18 distributors in 11 countries
- \$19.8m of total contracted revenue January 2019

# Solutions are Fully Developed, Validated & In Operation

- ImExHS has deployed >200 sites in LATAM
- 18 distributors covering 11 Countries
- Used by over 600 Radiologists
- > 35,000 clinical devices



- Ongoing expansion into neighbouring LATAM countries with low risk go-to-market strategy
- First collaboration in Australia under testing H1 2019.
- Additional cutting-edge functionality implemented-Web MPR/Web 3D & MIP - Two pilot sites deployed Q4 2018, full commercial release Q1 2019.
- Applied for FDA approval in 2018, ahead of USA soft launch in H1 2019


- 71 Hospitals
- 180 Clinics
- 216 Customers
- > 5 million new radiological studies per annum






# **Company Highlights**

#### **Total Contracted Value** (AUD Equivalent)





# Annualised Recurring Revenue (AUD Equivalent)






GEOGRAPHY	MARKET (US\$m) <sup>1</sup>	GROWTH (CAGF
LATAM	417	8.1%
APAC	695	7.0%
North America	1,667	4.4%
Europe	967	5.8%
Other	236	6.8%
TOTAL	3,982	5.8%

<sup>1</sup>Acute Market Report (2015), Picture Archiving Communication Systems (PACS) & Radiology Information Systems (RIS), Growth, Future Prospects & Competitive Analysis, 2016 - 2026 <sup>2</sup> Future Market Insights (2017), Global Teleradiology Market Industry Analysis and Opportunity Assessment, 2016-2026



- Escalating healthcare costs in all markets are driving demand for cost effective solutions and outsourcing
- Large percentage of radiology systems in developing countries use archaic analogue work flows, creating churn event opportunity to migrate to nextgeneration digital cloud solution
- Demand for web-based TeleRadiology is growing rapidly (predicted CAGR of 21%<sup>2</sup>)
- The application of Artificial Intelligence to radiological interpretation creates opportunities on numerous fronts
- ImExHS is initially targeting sales expansion into LATAM markets neighbouring existing operations, followed closely by APAC (Australia and Philippines), then North America and finally Europe







## How We Do It

# Modular

Able to grow and scale as scan volumes increase and as new diagnostic scanners or radiology facilities are added

# Independent System

Hiruko can run on any infrastructure - private or public cloud and even on the customer's own dedicated server infrastructure

.... Compared to most RIS PACS solutions which are built on heavy, inflexible and expensive client server architecture.



# **API Enabled**

Easy to integrate with other customer or third party systems to extend its value in the customer environment





## Hiruko supporting the efficiency and user experience for Radiologists

- Radiologists can
  - o work from anywhere, on any device or browser
  - customise Hiruko to their own requirements and preferences Ο
- The fully integrated nature of Hiruko increases both the speed and efficiency of the Radiology workflow
  - No need for the Radiologist to jump between different applications and windows Ο
  - Second opinions can be sought from Colleagues regardless of what platform they use Ο
- from anywhere on any device



The Radiologist can use voice recognition (clinical language understanding) to append the diagnosis to the image,

Hiruko has integrated billing including support for publically funded health insurance programs (similar to Medicare)



Radiology businesses (hospitals & clinics) prefer the ImExHS Hiruko platform because:

- Exceeds the capability & usability of competing high end platforms – Integrated Business Intelligence
- Disruptive price point up to 75% cheaper than competitors
- Cloud-based with zero in-house IT impact
- Single end to end solution including integrated scheduling and billing tools; avoid integration of multiple solutions
- Supports non-standard file formats that have clinical significance



Radiologists love the ImExHS Hiruko platform because they can:

- Work from anywhere, using any device (Mac, PC, tablet or smartphone)
- Use speech recognition with full Clinical Language understanding embedded in the application
- Use post-processing of images to aid in diagnosis
- Efficiently consult with colleagues for second opinions
- Hiruko software is fast, stable and easy to access



# **Business Model**

### Revenue Contract Models



1. Software as a Service (SaaS) 3-5 year contacts (paid monthly)



2. Platform as a Service (PaaS) 3-5 year contacts (paid monthly)



3. One-off Sales & Maintenance Paid in Full

Target Geographies

> LATAM (Now)

APAC (Next)

Australia, USA, and Europe (market driven)



### Target Markets

#### HEALTH CARE FACILITIES

Private Hospitals & Clinics

Public Hospitals & Clinics

**Private Practices** 

### Target Verticals

Radiology

Anatomical Pathology (APLIS)

Cardiology

Security Body Scanning (new)

## Distribution Model

#### DIRECT SALES

Global Growth developing branches in each new country

Cloud Market Place Globally

Augment with channel strategy

#### CHANNELS

Specialist Distributors

**TELCOs** 

OEMs

White Label


























# **New Product Verticals**

TESTING	DEVELOPMENT	PILOT	COMMERCIA
		PATHOLOG	
	CA	RDIOLOGY	



# Commercialisation

- RADIOLOGY Q4 2018 Web 3D MPR & MIP, triangulation tool implemented. 2 Pilot sites deployed. Q1 2019 released.
- ANATOMICAL PATHOLOGY Q4 2017 Secured first commercial customer Q3 2018 2<sup>nd</sup> Pilot test customer commenced Q1 2019 Full Commercial launch

CARDIOLOGY Q1 2018 Pilot testing at Las Americas (VNA installed) Q3 2018 Develop information work platform Q1 2019 Commercial launch



# Artificial Intelligence

- NATURAL LANGUAGE PROCESSING ALGORITHMS Specified pathologies Predictive Diagnostic alerts Diagnostic concordance analysis
- MACHINE LEARNING ALGORITHMS **Tumour Segmentation and Classification** Lung Nodule detection Bone Fracture severity identification
- AUTOMATIC IMAGE ANNOTATION RECOMMENDATIONS



# Research

- BRAVIZ v2.0 Platform for advanced analytics and visualisation of neurological images
- **NEW VISUALISATION TOOLS** Analytics on visual presentation



# ImExHS Tomorrow – New Markets

	201
	Q4
LATAM	
Brazil	
Other South America	
Other Central America	Appoint Distribute
APAC	
Phillipines	
Australia	Pilot
APAC 2	
APAC 3	
NORTH AMERICA	
FDA	Submi
USA	



	2018		20	19	
	Q4	Q1	Q2	Q3	Q4
LATAM					
Brazil		Appoint E	Distributor	Launch	
Other South America		Appoint Distributor	Launch		,
Other Central America	Appoint Distributor	Launch			
APAC					
Phillipines		Appoint E	Distributor	Launch	
Australia	Pilot				
APAC 2				Rele	ease
APAC 3				Rele	ease
NORTH AMERICA					
FDA	Submit	Аррі	oval		
USA				Soft Launch	



# Medical Imaging Corporate Activity













#### January 2018

## UK-private equity Permira Healthcare paid \$1.3bn consideration for I-Med Radiology, Australia's largest medical imaging clinic network

### November 2017

Philips (mkt cap \$47bn) and Nuance (mkt cap \$6.6bn) joint-venture to bring Al into radiology reporting

### November 2017


Amazon (mkt cap \$843bn) partnering with Cerner Health (mkt cap \$28bn) to analyse clinical data and predict treatments using AWS cloud-hosted data













7	
/	

# May 2017

# February 2016

August 2015

GE Health (mkt cap \$175b) and Partners HealthCare (\$12bn Revenue) 10-year joint-venture to build AI software across medical imaging software process

IBM acquired Truven Health for \$3.3bn to buy cloud-based healthcare data, analytics and insights on 200 million people

IBM acquired Merge Healthcare for \$1.25bn for medical image patient data across 7,500 US healthcare sites







# IME Summary





High margin contracted future revenues from core SaaS model

Next generation workflow and image management solution for healthcare facilities, built by radiologists, for radiologists

Successfully demonstrated market penetration into Mexico, Ecuador, Peru and Costa Rica with post-raising strategies for rapid expansion in other LATAM and Asia-Pacific

Strong sales pipeline, including renewals will add to existing contracted revenue, no customer churn

Funding largely dedicated to core business expansion, rather than technical development



# Public Company – Trading Comparables

	VOLPARA (ASX:VHT)	PRO MEDICUS (ASX:PME)	ImExHS (ASX:IME)
Description	Breast X-ray imaging, transitioning to SaaS based contracts	Radiology imaging software, strong 5 year contracted revenue order book	Radiology imaging software, High growth SaaS based revenue
Market Cap	\$199m <sup>1</sup>	\$1,500m <sup>1</sup>	\$22m <sup>1</sup>
TRADING MULTIPLES			
Total Contracted Value (TCV)	n/a*	<b>\$135m<sup>3</sup></b>	\$20m <sup>2</sup>
TCV Multiple	n/a	10.5x	1.1x
Annualised Recurring Revenue (ARR)	\$5.3m <sup>2</sup>	\$29.1m <sup>3</sup>	\$4.3m <sup>2</sup>
ARR Multiple	37.3x	51.5x	5.2x

Notes: 1. 4 Mar 2019 (Source: ASX)

- 2. 31 Dec 2018 (Sources: VHT-4C Announcement, PME-4D Announcement)
- 3. 30 Jun 2018 (Source: PME-Annual Report)
- \* Not applicable as TCV definition is not comparable





# Capital Table and Summary Financials

OVERVIEW CAP TABLE		
Market Price	\$0.025	
Market Cap	\$22m	
Shares on Issue:	925.7m	
Quoted	395.7m	
Escrowed (12-24m)	530m	
Milestone Options (two tranches)	100m	
Options	133.5m	

\* The transaction cost and share based payments related to the acquisition and relisting of IME during 2018 totalled \$3.93m.



#### Financial at FYE 31 December 2018 – A\$m

Revenue	\$6.1m	+ 70% yoy
Cash	\$2.4m	n/a
Trade & Other Receivables	\$3.9m	n/a
Total Contract Value (TCV)	\$20m	+343% yoy
Annual Recurring Revenue (ARR)	\$4.3m	+115% yoy
Trade & Other Payables	\$1.9m	n/a
Net Loss	(\$4.9m)*	
Total Equity	\$5.9m	+ 818%



# Board & Key Management

#### TOM PASCARELLA Chairman

#### **Company Director**

- Experienced professional in Corporate & Investment Banking, focused on Credit Products, Structured Finance and M&A Advisory services. Since his time in banking, with Allen Partners Tom has focused on capital raising for asset managers and SMEs.
- Former CEO and Managing Director of Bank of America N.A. Sydney Branch.
- Fellow FinSIA, (Financial Services Institute of Australasia)
- Member of the Australian Institute of Company Directors

#### **DR. GERMAN ARANGO** CEO, Director

Professor of Neuro-Radiology

- Entrepreneur with > 10 years experience running Radiology businesses
- ImExHS Founder

#### HOWARD DIGBY **Non-Executive Director**

#### **Company Director**

- 25 year experience managing technology related businesses across Asia Pacific region
- Senior management roles at Adobe, Gartner, Economist Group
- B Eng (Hons) (UWA)



#### CARLOS PALACIO **Non-Executive Director**

Founder and CEO of CrossPoint **Telecommunications** 

- Managed IT and Cloud provider to multinationals across 42 countries
- Major investor in ImExHS to date.
- B Eng, MBA (Macquarie)

#### **ANDRES VANEGAS Chief Sales Officer**

Mechatronic Engineer

- Specialist project and service manager in Radiology industry
- Over 10 years experience in deployment of imaging solutions for healthcare
- Ex-CTO Fujifilm Colombia

#### Dr Douglas Lingard **Non-Executive Director**


Experienced Radiologist and Nuclear Physician. Co-founder of Pittwater Radiology Partners which listed on the ASX and became the largest supplier of radiology services in Australia and a major supplier of diagnostic imaging to the NHS in the United Kingdom.

#### **DR. JORGE MARIN Chief Medical Officer**

Professor of Neuro-Radiology

- Surgeon & Neuro-Radiologist Barcelona & Bogota
- Manages ImExHS's University collaboration business agreements











# Disclaimer

The information contained in this Presentation or subsequently provided to the Recipient of this Presentation, whether orally or in writing by or on behalf of ImExHS Limited or its respective employees, agents or consultants ("Information") is provided to the Recipient on the terms and conditions set out in this notice.

The Recipient should not treat the Information as advice relating to legal, taxation, financial product or investment matters and should consult their own advisers. This Presentation does not purport to contain all the information that a prospective investor may require. The Information may not be appropriate for all persons and it is not possible for ImExHS Limited to have regard to the investment objectives, financial situation and particular needs of each Recipient who reads or uses the Information . Accordingly, no recommendation or expression of opinion is contained within the Information. Further, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the Information, including the likelihood of achievement or reasonableness or any forecasts, prospects or returns contained in the Information. Before acting in reliance on any Information, the Recipient should conduct their own investigation and analysis in relation to the investment opportunity presented by this Presentation and should check the accuracy, reliability and completeness of the Information and obtain independent and specific advice from appropriate professional advisers.

Statements contained in the Information, particularly those regarding possible or assumed future performance or potential growth, prospects or projections of ImExHS Limited are, or may be, forward looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks, uncertainties and contingencies. The Information may also be subject to clarification and change and ImExHS Limited may in its absolute discretion, but without being under any obligation to do so, update, amend or supplement the Information.

The Information is for informational purposes only and does not constitute an offer to issue, or arrange to issue, securities or other financial products. The Information is not, and should not be construed to be, a Prospectus.

To the maximum extent permitted by law none of ImExHS Limited or its respective employees, agents or consultants nor any other person accepts any liability, including, without limitation, any liability arising out of fault of negligence, for any loss arising from the use of the Information.





